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Background
Epidemiology and pathogenesis of renal cell carcinoma
Kidney cancers account for about 2% of all cancers, and 
more than 200,000 new cases of kidney cancer are diag­
nosed worldwide each year [1]. The most common form 
of kidney cancer in adults is renal cell carcinoma (RCC). 
Most  RCC  cases  (approximately  75%)  are  classified  as 
clear cell (conventional) RCC (ccRCC), and the next most 
frequent subtype is papillary RCC (pRCC; approximately 
15% of all cases) [2]. The most common genetic event in 
the  evolution  of  sporadic  ccRCC  is  inactivation  of  the 
von Hippel­Lindau (VHL) tumor suppressor gene (TSG) 
[3­6].  VHL  inactivation  leads  to  stabilization  of  the 
hypoxia­inducible transcription factors HIF­1 and HIF­2 
and activation of a wide repertoire of hypoxia response 
genes [7]. The frequency of VHL mutations in sporadic 
ccRCC has been reported to be as high as 75% (although 
VHL mutations are rare in non­clear­cell forms of RCC). 
In addition to VHL mutations, VHL allele loss of 3p25, 
resulting in biallelic VHL inactivation, is the most fre­
quent copy number abnormality in ccRCC (as predicted 
by a classical ‘two hit’ model of tumorigenesis, where loss 
of  the  second  allele  of  a  key  tumour  suppressor  is 
required for tumour formation to occur) [8,9].
Although  the  VHL  mutations  in  primary  RCC  were 
detected about 16 years ago, attempts to identify other 
frequently mutated RCC genes have been unsuccessful, 
with none of the thousands of genes tested so far mutated 
in over 15% of tumors [10]. TSG inactivation may result 
from genetic or epigenetic events, and it is well recog­
nized that epigenetic silencing of TSGs has a significant 
role  in  the  pathogenesis  of  many,  if  not  all,  human 
cancers.  Indeed,  promoter  methylation  and  epigenetic 
silencing of VHL in RCC [5] was one of the first examples 
of this phenomenon and so far approximately 60 genes 
have been suggested to be epigenetically dysregulated in 
RCC (Table 1).
Epigenetics and cancer
There  are  two  major,  interrelated  modes  of  epigenetic 
regulation in the mammalian genome: cytosine methy­
lation  and  histone  modification.  Only  cytosine  bases 
located 5’ to a guanosine can be methylated, and CpG 
dinucleotides  are  generally  underrepresented  in  the 
genome.  However,  short  regions  found  frequently  in 
proximal  promoter  regions  are  CpG  rich  [11].  These 
regions (CpG islands, 0.4 to 4 kb long and found in over 
50% of all genes) are generally unmethylated in normal 
cells but may be hypermethylated in tumors, where CpG 
island methylation is also associated with histone modifi­
cation and chromatin remodeling resulting in transcrip­
tional silencing [12­16]. Epigenetic states are, like gene 
mutations,  inherited  in  cell  division  but,  unlike  muta­
tions, DNA methylation and other epigenetic changes are 
potentially reversible [17,18].
In  a  non­disease  setting,  gene  silencing  by  promoter 
methylation occurs to regulate the expression of germline 
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© 2010 BioMed Central LtdTable 1. Gene methylation frequencies in RCC 
    Mean RCC  Number of  Range across      Adj normal   
    methylation  tumors  multiple      methylation*   
Gene  Locus   (%)  analyzed   studies (%)  ccRCC (%)  pRCC (%)  % (n)  References
APAF1  12q23  98  170  97-100  98  -  9 (80)  [106,107]
APC  5q21-22  17  253  14-29  16  32  7 (72)  [34,40-43]
BNC1  15q25  46  59  -  -  -  5 (20)  [63]
BTG3  21q11.2-21.1  70  20  -  -  -  0 (20)  [108]
CASP8  2q33-34  6  139  0-16  0  -  -  [53,107]
CDH1  16q22.1  35  229  11-80  83  69  87 (62)  [33,41-43,53]
CDH13  16q24.2-24.3  3  40  -  -  -  -  [53]
COL14A1  8q24  44  41  -  -  -  5 (20)  [63]
COL15A1  9q22  53  65  -  -  -  30 (30)  [63]
COL1A1  17q21.31-22  57  30  -  65  40  -  [106]
CRBP1  3q21-22  9  22  -  -  -  -   [54]
CST6  11q13  46  61  -  -  -  11 (35)  [63]
CXCL16  17p13.2  42  62  -  43  40  43 (21)  [109]
DAL-1/4.1B  18p11.3  45  55  -  45  -  -  [110]
DAPK1  9q34.1  35  219  24-41  38  -  -  [54,108,111]
DKK1  10q11.2  44  62  0-52  44  -  8 (62)  [63,65]
DKK2  4q25  58  52  -  58  -  6 (52)  [64]
DKK3  11p15.2  50  62  -  53  -  16 (62)  [62]
DLC1  8p22-21.3  35  34  -  -  -  3 (34)  [112]
ESR1  6q25.1  69  65  -  67  77  77 (62)  [43]
ESR2  14q23.2  53  65  -  56  46  43 (62)  [43]
FHIT  3p14.2  53  87  52-53  53  54  52 (0-69) (82)  [43,53]
FLCN  17p11.2  9  120  0-33  21  -  -  [113-115]
GREM1  15q13  24  165  20-41  20  -  15 (79)  [63,101]
GSTP1  11q13  10  177  8-12  6  15  0 (72)  [33,42,43]
HOXB13  17q21.2  30  50  -  -  -  0  [102]
IGFBP1  7p14-12  30  30  -  35  20  -  [106]
IGFBP3  7p14-12  12  120  3-37  13  40  -  [108,116]
JUP  17q21  91  54  -  -  11  11 (54)  [100]
KTN19  17q21.2  38  66  -  39  33  14 (22)  [109]
LOXL1  15q24  35  23  -  -  -  24 (17)  [63]
LSAMP  3q13.2-21  26  53  -  26  -  -  [67]
MDRI  7q21.1  86  65  -  87  85  97 (62)  [43]
MGMT  10q26  8  225  2-33  2  0  0 (62)  [33,41-43,54]
MT1G  16q13  20  25  -  -  -  -  [54]
p14ARF  9p21  33  299  17-68  36  40  20  [33,34,40,43]
p16INK4  9p21  11  407  0-80  10  13  0 (87)  [34,35,
                40-43,54,81]
PDLIM4  5q31  43  41  -  -  -  0 (22)  [63]
PML  15q22  3  90  -  3  -  -  [107]
PTGS2  1q25.2-25.3  95  65  -  96  92  100 (62)  [43]
RARB  3p24  13  206  0-53  2  0  0 (77)  [34,41-43,54]
RASSF1  3p21.3  51  735  28-91  59  75  48 (0-100)(174)  [34,35,38,
                40-46]
RASSF5  1q32.1  28  79  19-32  -  -  -  [54,67]
ROBO1  3p12  18  44  -  18  -  -  [117]
RPRM  2q23  44  52  -  -  -  18 (44)  [63]
SDHB  1p36.1-35  4  25  -  -  -  -  [53]
SFRP1  8p12-11.1  47  234  34-80  50  18  5 (152)  [59-63]
SFRP2  4q31.3  53  62  -  56  -  10 (62)  [62]
Continued overleaf
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expression  of  imprinted  genes  [19­22].  However,  in  the 
past  decade  it  has  become  accepted  that  aberrant 
promoter methylation and the resultant gene silencing can 
provide  a  selective  advantage  to  neoplastic  cells  in  the 
same manner that mutations do [22­26]. Thus, epi  genetic 
silencing  of  ‘gatekeeper’  or  ‘caretaker’  TSGs  can  occur 
frequently  at  the  earliest  stages  of  cancer  initiation, 
resulting in the clonal evolution of a population of cells at 
risk  of  obtaining  further  genetic  or  epigenetic  lesions 
[27,28]. In inherited cancer syndromes such as von Hippel­
Lindau disease (associated with susceptibility to RCC) de 
novo  VHL  promoter  hypermethylation  can  provide  the 
‘second hit’ that initiates tumor development [29]. In such 
cases methylation is specific to the wild­type allele, suggest­
ing clonal selection for the epigenetic loss of expression.
A survey of methylated genes in RCC
In  order  to  catalog  candidate  TSGs  reported  to  show 
tumor­specific  region  hypermethylation  in  RCC,  we 
searched  PubMed  and  other  online  databases  (such  as 
PubMeth) [30]. Of the 58 genes that were identified as 
being methylated in RCC (Table 1, Figure 1; see Table 1 
for full gene names), 43 had a mean combined methylation/
mutation rate of over 20% and the characteristics of these 
genes were analyzed in further detail (although 31 genes 
had been reported only by a single study).
Chromosome 3p tumor suppressors
Deletions of 3p are frequent in many adult cancers [31] 
and  occur  in  45  to  90%  of  sporadic  RCCs  [4,32,33]. 
Inactivation  of  the  3p25  TSG  VHL  is  of  critical 
importance to the pathogenesis of ccRCC and occurs in 
up to 86% of tumors [34]. Although VHL mutations are 
rare in non­clear­cell RCC, VHL methylation has been 
reported in pRCC and ccRCC [9,35,36]. VHL methylation 
does not associate with tumor stage, consistent with the 
interpretation that it is an early event in tumor formation 
[9,37].  In  addition  to  VHL,  several  other  3p  candidate 
TSGs  have  been  reported  to  be  methylated  in  RCC 
(Figure 1). The RASSF1 gene maps to 3p21, a region of 
frequent allele loss in RCC and other cancers (including 
lung,  bladder,  breast  and  hepatocellular).  Somatic 
RASSF1A  mutations  are  infrequent  in  cancer  [38],  but 
RASSF1 is frequently methylated in sporadic RCC (and 
various other common cancers), either biallelically or as a 
second  hit  following  3p  deletion  [39,40].  After  VHL, 
RASSF1 methylation has been examined more than any 
other  gene  in  sporadic  RCC,  the  mean  methylation 
frequency is 51% [34,35,38,41­47]. In a study by Costa et 
al. [44], frequent RASSF1A methylation was detected in 
kidney tissue surrounding the excised tumor. Aberrant 
methylation  in  morphologically  normal  renal  tissue 
adjacent to the tumor (but not in more distant normal 
tissue)  has  been  interpreted  as  evidence  that  the  TSG 
methylation is part of a ‘field effect’ at an early stage of 
tumorigenesis that produces a large number of cells with 
an  initial  epigenetic  lesion  that  is  then  followed  by 
additional genetic and/or epigenetic events that lead to 
tumor  development.  The  candidate  tumor  suppressor 
gene  TU3A  (located  at  3p21.1)  is  frequently  down­
regulated in cancers, most notably prostate cancer [48] 
Table 1. Continued 
    Mean RCC  Number of  Range across      Adj normal   
    methylation  tumors  multiple      methylation*   
Gene  Locus   (%)  analyzed   studies (%)  ccRCC (%)  pRCC (%)  % (n)  References
SFRP4  7p14-13  53  62  -  56  -  15 (62)  [62]
SFRP5  10q24.1  57  62  -  59  -  15 (62)  [62]
SLIT2  4q15.2  25  48  -  -  -  8 (12)  [118]
SPINT2  19q13.2  38  118  -  30  45  5 (38)  [70]
TIMP3  22q12.1-13.2  51  289  20-78  36  32  14 (104)  [34,40-43,119] 
TU3A  3p21.1  39  61  -  42  25  0 (24)  [49]
UCHL1  4p14  38  32  -  -  -  0 (32)  [116]
VHL  3p26-25  16  740  8-31  14  16  0  [5,9,33-36,40]
WIF1  12q14.3  73  62  -  76    23 (62)  [62]
XAF1  17p13.2  12  84  8-50  -  -  0 (4)  [120,121]
*Where the range of methylation in adjacent (Adj) normal tissue is high across multiple studies, this range is indicated in parentheses before the number analyzed. 
Abbreviations: APAF1, apoptotic protease activating factor 1; APC, adenomatous polyposis coli; BNC1, basonuclin 1; BTG3, B-cell translocation gene 3; CASP8, caspase 8; 
CDH1, cadherin 1; CDH13, cadherin 13; COL, collagen; CRBP, retinol binding protein 1, cellular; CST6, cystatin E/M; CXCL, chemokine (C-X-C motif) ligand; DAL, differentially 
expressed in adenocarcinoma of the lung; DAPK, death-associated protein kinase; DKK, dickkopf; DLC, deleted in liver cancer ; ESR, estrogen receptor; FHIT, fragile histidine 
triad; FLCN, folliculin; GREM, gremlin; GSTP, glutathione s-transferase protein; HOXB, homeobox family B; IGFBP, insulin-like growth factor binding protein; JUP, junction 
plakoglobin (also called γ-catenin); KTN, keratin; LOXL, lysyl oxidase-like; LSAMP, limbic system-associated membrane protein; MDRI, multiple drug resistance gene; 
MGMT, O-6-methylguanine-DNA methyltransferase; MT1G, metallothionein 1G; p14ARF, cyclin-dependent kinase inhibitor 2A alternative reading frame; p16INK4, cyclin-
dependent kinase inhibitor 2A; PDLIM4, pdz and lim domain protein 4; PML, promyelocytic leukemia; PTGS, prostaglandin-endoperoxide synthase; RARB, retinoic acid 
receptor beta; RASSF, RAS association domain family; ROBO, roundabout; RPRM, reprimo; SDHB, Succinate dehydrogenase B; SFRP, secreted frizzled related protein; 
SLIT2, slit homolog 2; SPINT2, serine peptidase inhibitor, Kunitz type, 2; TIMP, Tissue inhibitor of metalloproteases; UCHL, ubiquitin carboxyl-terminal esterase L1; VHL, von 
Hippel-Lindau tumor suppressor; WIF, Wnt inhibitory factor; XAF, XIAP associated factor.
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was methylated in 42% of ccRCC and 25% of pRCC [50].
The  FHIT  gene  encodes  a  diadenosine  5’,5’’’­P1,P3­
triphosphate  hydrolase  involved  in  purine  metabolism. 
The gene encompasses the common fragile site FRA3B at 
3p14.  Loss  of  FHIT  is  common  to  many  tumor  types 
[51,52]. In vivo, re­expression of FHIT has tumor sup­
pres  sing  activity  [53].  FHIT  promoter  methylation  is 
common (52 to 53%) in both ccRCC and pRCC [44,54].
RARB regulates cell proliferation and differentiation 
and, in common with other 3p TSGs (RARB maps to 
3p24), is frequently downregulated or lost in multiple 
tumor  types.  However,  several  small  studies  have 
found RARB to be methylated in less than 20% of RCC 
cases [35,42,44,55].
WNT pathway regulators
Dysregulation  of  the  WNT/β­catenin  pathway  is 
common in a variety of cancers, and oncogenic activation 
of  this  pathway  drives  the  expression  of  genes  that 
contribute to proliferation, survival and invasion [56,57]. 
Inhibitors  of  WNT  signaling  can  be  divided  into  two 
functional classes: the SFRP proteins, which bind directly 
to WNT, preventing its binding to the FZ receptor [58], 
and  the  Dickkopf  (DKK)  proteins,  which  bind  to  the 
Low­density  lipoprotein  receptor­related  protein  5 
(LRP5)­LRP6 component of the Wnt receptor complex 
[59]. The SFRP1, SFRP2, SFRP4, SFRP5 and related WIF1 
genes are all frequently methylated in RCC (47 to 73%) 
[60­64],  as  are  the  Dickkopf  genes  DKK1,  DKK2  and 
DKK3 (44 to 58%) [63­66]. Recently, SFRP1 was shown to 
be overexpressed in metastatic RCC compared with non­
metastatic  tumors,  in  which  expression  was  often 
attenuated by promoter methylation [67].
Epigenetics and familial RCC genes
As  described  above,  germline  VHL  mutations  cause 
inherited RCC and VHL inactivation is also critical to 
the  development  of  most  ccRCC.  Similarly,  a 
constitutional  translocation  associated  with  RCC 
susceptibility  disrup  ted  the  NORE1A  (RASSF5)  and 
LSAMP1  genes,  and  both  genes  were  epigenetically 
inactivated  in  sporadic  RCC  [68].  However,  somatic 
inactivation (by mutation or methylation) of other genes 
associated with inherited kidney cancer, such as FLCN, 
FH  and  SDHB,  is  infrequent  or  absent  (Table  1). 
Figure 1. Genes methylated in RCC are distributed across the genome. However, there is a concentration of silenced genes at 3p (see text for 
details). Methylated genes are also concentrated at chromosome 17 and both loss and gain of chromosome 17 have been reported in RCC.
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inhibitor  of  MET  activity  (activating  mutations  in  the 
MET proto­oncogene are associated with familial pRCC, 
although somatic mutations are infrequent in sporadic 
pRCC [69,70]), was found to be methylated in 30% of 
ccRCC  and  45%  of  pRCC  [71].  This  observation 
demonstrates how TSG methylation can target familial 
RCC  gene  pathways.  We  note  that  several  other 
epigenetically  inactivated  candidate  TSGs,  includ  ing 
members of the Wnt regulatory pathway [72], p16INK4a 
[73],  CASP8  [74],  GREM1  [75],  RPRM  [76],  collagens 
[77], IGFBP1 [78], IGFBP3 [79] and PTGS2 [80], can be 
related  to  VHL­regulated  pathways.  How  ever,  genes 
involved in many other cellular processes have also been 
found to be epigenetically silenced in RCC (Table 1).
Identification of novel RCC TSGs by epigenetic 
analyses
Compared with the results of high­throughput sequen­
cing studies of RCC [81], it seems that epigenetic studies 
have  provided  a  much  higher  number  of  frequently 
inactivated candidate TSGs. Nevertheless, a combination 
of  sequencing  and  epigenetic  analysis  provides  the 
optimum strategy. Thus, although RASSF1A would not 
have  been  identified  as  an  important  RCC  TSG  by 
sequencing analysis alone, CDKN2A (which is mutated in 
approximately 10% of RCC and is the second most highly 
mutated gene in RCC [10]), is, on average, methylated in 
11% of RCC [35,36,41,43,44,55,82], yielding a combined 
inactivation rate of about 21%. A wide variety of method­
ological  approaches  can  be  used  to  determine  the 
promoter methylation status of candidate RCC TSGs and 
these have differing advantages and drawbacks (Tables 2 
and  3).  In  addition  to  the  detection  of  pathological 
promoter region methylation, it is important to demon­
strate that this is associated with transcriptional silencing 
of the candidate TSG.
The  functional  epigenomics  strategy  uses  5­aza­2’­
deoxycytidine treatment of cancer cell lines to identify 
genes whose expression is reactivated following demethy­
lation. Although this strategy can provide an unbiased 
approach to identifying candidate epigenetically inactiva­
ted TSGs, only a minority of the re­expressed genes are 
ultimately  proven  to  be  silenced  in  primary  tumors. 
Some techniques, such as methylation­specific PCR, can 
be very sensitive, and it is reassuring when results are 
available  from  a  large  number  of  tumors  and  multiple 
studies  because  the  frequencies  of  methylation  for 
individual  genes  can  show  considerable  variation 
(Table 1). Such variation can reflect differences between 
cohorts  of  tumor  samples  or  methylation  detection 
methodologies, and only in a minority of cases are there 
data available from multiple studies and over 100 tumor 
samples.  For  less  well  studied  genes  the  evidence  for 
pathogenicity  is  strengthened  by  reports  of  frequent 
tumor­specific  methylation  (or  mutations)  in  other 
tumor  types;  this  is  the  case  for  BNC1  [83],  PDLIM4 
[84,85], CST6 [86,87] SLIT2 [88,89], IGFBP3 [90,91] and 
SPINT2 [92­94].
So far, epigenetic studies in RCC have concentrated on 
the  methylation  of  CpG  islands  at  or  near  to  gene 
promoters.  Recent  studies  in  colorectal  cancer  have 
indicated that methylation extends well beyond discrete 
islands. Indeed, approximately 50% of these ‘CpG island 
shores’  were  found  more  than  2  kb  from  the  nearest 
annotated gene [95]. As with CpG island methylation, 
CpG  shore  methylation  inversely  correlates  with  gene 
expression.  Further  investigation  of  global  genomic 
Table 2. Technologies to identify genome-wide epigenetically regulated genes
Method  Key features  Advantages  Disadvantages
Functional epigenomics Methylated genes are re-expressed in 
cell lines by treatment with 5-aza-2’-
deoxycytidine. Expression arrays determine 
reactivated genes 
Links hypermethylated sites to 
gene silencing 
Correlating correct methylated site to 
expression regulation is laborious. Cell 
lines are frequently more methylated 
than the corresponding tumors. 
Methylation-dependent 
immunoprecipitation (MeDIP) 
Methylated DNA is separated 
from unmethylated DNA by 
immunoprecipitation and hybridized to a 
CpG island microarray
Global analysis; produces 
quantifiable results
Dependent on good 
immunoprecipitation efficiency; difficult 
to determine the extent of methylation 
across a specific CpG island
Bead chip ‘Infinium’ Bisulfite-modified DNA is hybridized to 
beads containing DNA oligonucleotides 
specific to CpG dinucleotide methylation. 
Single base extension determines 
methylation state
Global analysis at single CpG 
sites using targeted probes; 
quantitative data
Provides data for only one or two CpG 
dinucleotides per island; further work 
may be required to determine the extent 
of methylation at specific sites
Next-generation sequencing Combines isolation of methylated DNA 
using techniques such as MeDIP or 
restriction digest and high-throughput 
sequencing. Bisulfite-modified DNA can 
also be sequenced directly
Statistically robust; high 
coverage; single nucleotide 
resolution
Initial set-up costs high; probe design can 
be challenging
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role  of  epigenetic  gene  silencing  (and  oncogene 
activation) in RCC development. It is now accepted that 
in  certain  tumor  types,  colorectal  being  the  best 
described,  a  subset  of  tumors  show  a  CpG  island 
methylator  phenotype  (CIMP+),  which  associates  with 
specific  lesions  such  as  BRAF  mutations  and 
microsatellite instability [96]. How  ever, the relevance of 
the CIMP+ phenotype to RCC has not yet been clearly 
defined [97]. The role of abnormal histone modification 
as an epigenetic factor in RCC development also remains 
to be investigated in depth. However, recent large­scale 
sequencing  screens  of  RCC  revealed  mutations  in  the 
histone­modifying  genes  ubiquitously  transcribed 
tetratricopeptide  repeat  gene  on  x  chromosome  (UTX), 
set  domain-containing  protein  2  (SETD2)  and  lysine-
specific  demethylase  5C  (KDM5C,  JARID1C),  and  that 
loss  of  these  genes  correlated  with  transcriptional 
deregulation  [81,98].  The  interplay  between  erroneous 
histone modification and aberrant DNA methylation in 
the evolution of RCC merits further investigation.
Translational medicine and RCC epigenetics
Epigenetic biomarkers
Methylated  TSGs  provide  attractive  options  for  bio­
markers  for  the  detection  and  prognosis  prediction  of 
cancers, including RCC [99]. DNA­based assays are often 
more  robust  than  RNA­based  assays,  and  whereas  the 
mutation spectrum causing TSG inactivation is usually 
diverse  (which  limits  the  utility  of  mutation­specific 
detection strategies for tumor screening programs), TSG 
inactivation  by  promoter  hypermethylation  provides  a 
more  homogeneous  target  for  molecular  screening 
strate  gies.  So  far,  large­scale  gene  sequencing  studies 
have demonstrated that, with the exception of VHL, there 
are  no  genes  that  are  mutated  very  frequently,  but  a 
significant  number  of  genes  do  show  frequent  tumor­
specific methylation.
Early diagnosis of RCC can be challenging. The classical 
clinical symptoms and signs of renal cancer are usually 
present only with late disease, when prognosis is poor; 
these symptoms ­ pain, palpable flank mass and hematuria 
­ are present in only approximately 10% of patients [100]. 
The aim is to detect RCC early when the tumor is still 
confined, as this has a significant impact on long­term 
disease­free survival. Although an increasing number of 
RCCs are detected as incidental findings on abdominal 
imaging, distinguishing benign and malignant masses in 
such a situation can be difficult. However, DNA can be 
detected from cells sloughed from the tumor into urine or 
blood,  and  three  studies  [41­43]  have  successfully 
detected  the  presence  of  promoter  methy  lation,  by 
methylation­specific  PCR,  from  DNA  extracted  from 
serum and urine of patients with RCC. Methylation of the 
Wnt antagonists SFRP1, SFRP2, SFRP4, SFRP5, DKK3 and 
WIF1  was  detected  in  tumor  DNA  in  the  serum  of 
patients in whom those genes were methylated in their 
tumor. Moreover, the frequency of methylation detection 
in serum correlated significantly with increased grade and 
stage,  suggesting  that  detection  of  these  methylation­
specific PCR products may be useful as markers of tumor 
progression  [63].  Using  a  panel  of  previously  identified 
RCC­specific  methylated  genes,  two  of  these  studies 
[41,43] have found a strong correlation between tumor 
methylation and methylated DNA obtained from patient 
urine. Methylation was not found in control, age­matched 
urine samples. The panels of genes used in these studies 
included  VHL,  RASSF1,  MGMT,  GSTP1,  p16INK4, 
p14ARF, APC and TIMP3. The specificity for genes such 
as VHL and RASSF1, which are frequently methylated and 
believed  to  be  inactivated  at  an  early  stage  of  tumor 
development,  suggests  that  methylation­specific  PCR­
based hypermethylation panel arrays could have potential 
as  an  economically  viable  early  detection  screen  for 
patients  presenting  non­specific  symptoms  and  for 
distinguishing benign and malign renal masses.
Table 3. Technologies to analyze specific methylated regions
Method  Key features  Advantages  Disadvantages
Methylation-specific PCR (MSP) DNA primers are designed to distinguish 
between methylated or un-methylated 
DNA. Bisulfite-modified DNA is amplified
Very sensitive; will identify very 
low levels of methylated DNA in 
a sample
Very sensitive; easily contaminated; 
requires further analysis to determine 
level of methylation present
Combined bisulfite restriction 
analysis (CoBRA)
Bisulfite-modified DNA is amplified using 
non-discriminatory primers. PCR product is 
digested with restriction enzymes that are 
specific to methylated DNA sequences
Robust detection of 
methylation; not prone to false 
positive results 
Does not give detailed analysis of region 
amplified; requires complete bisulfite 
conversion to prevent PCR bias
Bisulfite sequencing Bisulfite-modified DNA is amplified using 
non-discriminatory primers. PCR product is 
cloned and sequenced
Informative for all CpGs within 
the region; provides allele-
specific methylation information
Laborious
Pyro-sequencing Bisulfite-modified DNA is amplified 
using non-discriminatory primers and 
sequenced using pyro-sequencing 
technology
Multiple samples can be 
analyzed in parallel; quantitative
Analysis is restricted by small read sizes
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nostic biomarkers have been analyzed in urine or blood 
from  RCC  patients.  However,  the  tumor  methylation 
status  of  several  TSGs  has  been  correlated  with  prog­
nosis. Two independent studies [63,64] have reported an 
inverse correlation between SFRP1 promoter methylation 
and  patient  survival  (in  vitro  and  in  vivo  assays  both 
suggested that SFRP1 had tumor suppressing activity in 
RCC [62,64]). Methylation of COL14A1 and BNC1 was 
significantly associated with a poorer prognosis and this 
was  a  better  prognostic  indicator  than  tumor  stage  or 
grade [64]. JUP methylation was detected in a very high 
proportion of tumors tested (91%) and was reported to 
be an independent indicator of disease progression and 
patient survival [101]. Similarly, a significant correlation 
between methylation of the bone morphogenetic protein 
antagonist GREM1 and tumor grade and stage and poor 
prognosis was reported [102], and methylation of TU3A 
was significantly associated with advanced tumor stage 
(later than stage T2) and poor survival [50]. The methy­
lation  status  of  several  TSGs  has  been  correlated  with 
tumor  pathological  characteristics  but  not  prognosis. 
HOXB13 methylation, for example, was correlated with 
tumor grade, stage, size and microvessel invasion [103], 
whereas  DKK1  methylation  correlated  with  increased 
pathological grade [66] and DKK2 methylation correlated 
with both increased stage and grade [65]. However, most 
of these studies require replication and, although RASSF1 
methylation was reported to correlate with stage [44,46] 
and  grade  [44],  the  largest  study  so  far  found  no 
correlation with grade [39].
Clearly  it  is  important  that  there  should  be  further 
studies  of  potential  methylated  biomarkers  in  tumor 
tissue and urine and/or blood with the ultimate aim of 
producing a panel of biomarkers that will enable non­
invasive detection, molecular staging and prediction of 
prognosis. As the number of potential methylated TSG 
biomarkers increases, it will be of great importance to 
assay  these  in  a  standardized  manner  in  prospective 
studies to establish their clinical utility.
Promoter methylation as a target for therapy
The  identification  of  frequently  methylated  RCC  TSGs 
highlights  critical  pathways  that  could  potentially  be 
targeted for novel therapeutic interventions in RCC and 
other  cancer  types.  In  addition,  there  are  less  gene­
specific approaches to epigenetic therapy. Decitabine, the 
clinical form of the demethylating agent 5­aza­2’­deoxy­
cytidine, has been investigated in several clinical trials for 
neoplasia, and promising responses have been reported 
in hematological malignancies (such as myelodysplastic 
syndrome  [18,104,105]),  although  the  response  rates 
seem to be lower for common solid tumors. However, 
epigenetic therapy to alter cancer methylation or histone 
modification status is an area of increasing clinical trial 
activity.  Clearly,  strategies  such  as  tumor  methylation 
profiling, which could identify cancer patients most likely 
to respond to such therapies, would be a major advance.
Future prospects
Technological  advances  are  accelerating  the  pace  of 
methy  lation profiling for common human cancers. The 
advent  of  high­throughput  hybridization­based  assays 
can allow the methylation status of around 14,000 genes 
to be analyzed simultaneously (although only a few CpGs 
are interrogated for each gene) and strategies based on 
second  generation  massively  parallel  sequencing  tech­
nologies  will  undoubtedly  provide  a  more  complete 
assessment of RCC epigenetics and elucidate novel RCC 
TSGs. One advantage of these approaches over the older 
‘candidate  gene  epigenetic  status  approach’  is  that  the 
simultaneous  analysis  of  many  genes  allows  a  better 
comparison of TSG methylation frequencies for specific 
genes  and  is  likely  to  facilitate  comparison  between 
different studies. With increasing numbers of methylated 
TSGs in RCC identified, our knowledge of the molecular 
pathogenesis  of  RCC  will  increase  and  with  it  the 
potential for developing novel biomarkers and potential 
therapeutic interventions.
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